Loading
Lunit
Korean AI company spanning mammography reading (INSIGHT MMG), breast-density risk (Volpara), and AI pathology for immunotherapy biomarkers.
Overview
21 studies at ECR 2026 covering INSIGHT MMG, Scorecard (ex-Volpara density), and INSIGHT CXR; a large Dutch randomised trial using Scorecard showed supplemental MRI in dense breasts reduced advanced cancer incidence. Lunit SCOPE pathology AI partnered with Labcorp and CellCarta (2025-26) for companion diagnostics.
Headquarters
Seoul, KR
Scorecard
All companies#362of 1245 companies, score 10
- approved products +6
- modalities +2
- regions +2
1 approved, 0 in phase 3, 0 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Type
AI & software · 328130.KQ
Stage
Public
Website
Products
1ApprovedAI mammography detection software
Lunit INSIGHT MMG · Lunit INSIGHT MMG
A Korean AI mammography reader used in screening programmes in Sweden and Australia and cleared in the US and Europe.
Key papers
1Connected
22Similar pages
- Key paperMASAI: AI-supported mammography screening finds more cancers with half the radiologist workload
Shares Roll out AI-supported mammography nationally as a stepped-wedge trial, Set each woman's mammogram interval from her last mammogram, using AI risk, Mammography & tomosynthesis, AI that is built but not validated or deployed.
- CompanyAidoc
Shares No clinical claims for imaging-derived biomarkers without phantom and standards compliance, AI clears the normal lung screening scans so radiologists read only the suspicious ones, AI-assisted central imaging reads to cut endpoint cost and variability, AI that is built but not validated or deployed.
- IdeaPathologist assistants plus AI triage to multiply pathologist capacity
Shares AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions, AI that is built but not validated or deployed, Not enough oncologists, nurses, pathologists, physicists, Digital pathology & AI.
- IdeaA dedicated fund for randomised trials of cancer AI with patient outcomes
Shares Mammography & tomosynthesis, AI that is built but not validated or deployed, AI in radiology, Digital pathology & AI.
- CompanyPaige AI
Shares AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions, Turn the map of immune cells inside a tumour into a standardised test, AI that is built but not validated or deployed, Not enough oncologists, nurses, pathologists, physicists.
- CompanyTherapixel
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CompanyVara
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TreatmentProFound AI (iCAD)
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
cancers
fronts
technologies
drugs
ApprovedAI mammography detection software
Lunit INSIGHT MMG · Lunit INSIGHT MMG
companies
trials
ideas
AI clears the normal lung screening scans so radiologists read only the suspicious onesAI-assisted central imaging reads to cut endpoint cost and variabilityAI-first reading for high-volume common cancer diagnoses, pathologist for the exceptionsNo clinical claims for imaging-derived biomarkers without phantom and standards complianceRoll out AI-supported mammography nationally as a stepped-wedge trialSet each woman's mammogram interval from her last mammogram, using AI riskTurn the map of immune cells inside a tumour into a standardised test
bottlenecks
key papers
Software in use
The software of oncology →Commercial and regulated products that this organisation sells. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
A family of reading algorithms sold into screening and diagnostic imaging: mammography, tomosynthesis and chest radiographs, each cleared separately.
Lunit's pathology side: algorithms that read stained slides for PD-L1 expression and for the immune phenotype of the tumour microenvironment.
Lunitno source outside the company found
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
prnewswire.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-11 · Jude Gomila · Link orphan journals, startups, investors, collections an… · diff · file
Sourced, not expert-reviewed